Global Crigler–Najjar Syndrome Market Segmentation, By Drugs (Bilirubin Chelators, Ursodeoxycholic Acid and Others),Treatment (Surgery, Drugs, and Others), Mode of Administration (Injectable, Oral, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2031
Crigler–Najjar Syndrome Market Analysis
In the crigler–najjar syndrome market, advancements in gene therapy offer promising solutions. These innovative treatments aim to correct the underlying genetic defect, providing hope for patients by potentially eliminating the need for lifelong phototherapy. Such progress improves quality of life and also signifies a significant step forward in managing this rare genetic disorder.
Crigler–Najjar Syndrome Market Size
The global crigler–najjar syndrome market size was valued at USD 981.23 million in 2023 and is projected to reach USD 1,794.77 million by 2031, with a CAGR of 7.84% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Segments Covered
|
Drugs (Bilirubin Chelators, Ursodeoxycholic Acid and Others),Treatment (Surgery, Drugs, and Others), Mode of Administration (Injectable, Oral, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
International Stem Cell Corporation (U.S.), Promethera (Belgium), Selecta Biosciences, Inc. (U.S.), LogicBio Therapeutics, Inc. (U.S.), Genethon (France), Audentes Therapeutics (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Zydus Cadila (India), Endo Pharmaceuticals Inc. (Ireland), ANI Pharmaceuticals, Inc. (U.S.), Mylan N.V. (Netherlands ), Glenmark Pharmaceuticals Ltd (India), Amneal Pharmaceuticals LLC (U.S.), Epic Pharma, LLC (U.S.), and Lannett Company (U.S.)
|
|
Market Opportunities
|
|
Crigler–Najjar Syndrome Market Definition
Crigler-Najjar syndrome is a rare genetic disorder characterized by deficient enzyme activity, leading to severe jaundice and potential neurological damage due to high levels of unconjugated bilirubin in the blood. Treatment often involves phototherapy and liver transplantation. Without intervention, it can result in life-threatening complications, making early diagnosis and management crucial for affected individuals.
Crigler–Najjar Syndrome Market Dynamics
Drivers
- Advancements in Liver Transplantation
Advancements in liver transplantation, including refined surgical techniques, enhanced organ preservation methods, and improved immunosuppressive therapies, hold promise for improving outcomes and broadening eligibility criteria for patients with severe Crigler-Najjar syndrome. These developments may increase the accessibility and effectiveness of liver transplantation as a treatment option for this rare genetic disorder.
- Collaborative Research Initiatives
Collaborative research initiatives involving academia, industry, and government organizations can expedite Crigler-Najjar syndrome research, uncovering new therapeutic targets and treatment approaches. By pooling resources, expertise, and data, these partnerships catalyze innovation, potentially offering life-changing solutions for individuals affected by this rare genetic disorder.
Opportunities
- Patient Advocacy and Support Groups
Patient advocacy groups are vital for Crigler-Najjar syndrome, raising awareness, supporting research, and advocating for improved treatments and access to care. Their efforts can boost funding for research and development, advancing understanding and treatment options for this rare genetic disorder, ultimately enhancing the quality of life for those affected by the condition.
- Advancements in Gene Therapy
Gene therapy, including CRISPR-Cas9, shows potential in treating genetic disorders like Crigler-Najjar syndrome. These advancements aim to correct underlying genetic mutations, offering the possibility of curative treatments. Continued progress in gene editing technologies holds promise for addressing the root cause of the condition, potentially transforming the management of rare genetic diseases.
Restraints/Challenges
- Limited Awareness and Diagnosis
Limited awareness among healthcare professionals about Crigler-Najjar syndrome's rarity leads to frequent misdiagnosis or missed diagnosis. Consequently, patients face delays or inadequate treatment, hindering market expansion and compromising patient care. Increased education and awareness initiatives are crucial to improve early detection and management of this rare genetic disorder.
- High Cost of Treatment
The exorbitant expense of treating Crigler-Najjar syndrome, notably through liver transplantation, poses a formidable barrier to access for patients and healthcare systems. This financial burden stifles market growth and the uptake of therapies, hindering widespread adoption and exacerbating the challenges faced by individuals affected by the condition.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Crigler–Najjar Syndrome Market Scope
The market is segmented on the basis of drug, treatment, mode of administration, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Bilirubin Chelators
- Ursodeoxycholic Acid
- Others
Treatment
- Surgery
- Drugs
- Others
Mode of Administration
- Injectable
- Oral
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Crigler–Najjar Syndrome Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, drug, treatment, mode of administration, distribution channel and end user as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the Crigler–Najjar syndrome market, primarily attributed to its well-established healthcare infrastructure. With advanced medical facilities and research institutions, the region offers optimal treatment options and support for patients affected by this rare genetic disorder.
Asia-Pacific is expected to witness high growth in the Crigler–Najjar syndrome market due to developing healthcare infrastructure and the region's large population. This creates opportunities for improved diagnosis, treatment, and awareness programs, addressing the needs of patients effectively.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Crigler–Najjar Syndrome Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- International Stem Cell Corporation (U.S.)
- Promethera (Belgium)
- Selecta Biosciences, Inc. (U.S.)
- LogicBio Therapeutics, Inc. (U.S.)
- Genethon (France)
- Audentes Therapeutics (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Zydus Cadila (India)
- Endo Pharmaceuticals Inc. (Ireland)
- ANI Pharmaceuticals, Inc. (U.S.)
- Mylan N.V. (Netherlands )
- Glenmark Pharmaceuticals Ltd (India)
- Amneal Pharmaceuticals LLC (U.S.)
- Epic Pharma, LLC (U.S.)
- Lannett Company (U.S.)
Latest Development in Crigler–Najjar Syndrome Market
- In August 2022, KSL Beutner Laboratories (Beutner) launched a blood test designed to detect an antigen associated with mucous membrane pemphigoid (MMP), a distressing autoimmune blistering disease known to cause lesions in the oral cavity. This innovation promises improved diagnostic accuracy and early detection of MMP, enhancing patient care and management
SKU-